Document Type : Original Article


1 National Institute of Genetic Engineering and Biotechnology

2 Behavioral Sciences Research Center, lifestyle Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran



In recent decades, there has been an increase in the incidence of cancer in the affected communities. However, the growth of therapeutic strategies has been very slow. Conventional diagnosis and subsequent treatment in medical centers originated from pathological based examinations, symptoms, and medications.


1.Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y,
Fradet V, et al. SRD5A polymorphisms and biochemical failure
after radical prostatectomy. Eur Urol. 2011;60(6):1226-34.
doi: 10.1016/j.eururo.2011.06.020 pmid: 21715084
2. Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P,
Buettner R, et al. Regulatory BCL2 promoter polymorphism (-
938C>A) is associated with adverse outcome in patients with
prostate carcinoma. Int J Cancer. 2011;129(10):2390-9. doi:
10.1002/ijc.25904 pmid: 21207420
3. Verma M. Personalized medicine and cancer. J Pers Med.
2012;2(1):1-14. doi: 10.3390/jpm2010001 pmid: 25562699
4. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M,
Winter S, et al. Association between CYP2D6 polymorphisms
and outcomes among women with early stage breast cancer
treated with tamoxifen. JAMA. 2009;302(13):1429-36. doi:
10.1001/jama.2009.1420 pmid: 19809024
5. Offit K. Personalized medicine: new genomics, old lessons.
Hum Genet. 2011;130(1):3-14. doi: 10.1007/s00439-011-
1028-3 pmid: 21706342
6. Manace LC, Godiwala TN, Babyatsky MW. Genomics of
cardiovascular disease. Mt Sinai J Med. 2009;76(6):613-23.
doi: 10.1002/msj.20151 pmid: 20014425